Cartherics with lead programs in ovarian cancer and endometriosis, has announced the granting of a patent for ‘Method for Providing Immune Cells with Enhanced Function’ by the Chinese Patent Office.
After Cellular Origins announced its latest collaboration with Johnson & Johnson, Olivia Friett spoke to Edwin Stone, CEO, Cellular Origins about the collab and the future of mobile robotics.
Joel Eichmann, co-founder & managing director of Green Elephant Biotech explores the integration of sustainable alternatives to fossil fuel-based plastics.
Cellular Origins, a TTP Company, focused on enabling scalable, cost-effective, and efficient manufacture of cell and gene therapies (CGTs), has announced an international collaboration with Thermo Fisher Scientific.
Shift Bioscience, a biotechnology company uncovering the biology of cell rejuvenation to develop new therapies for age driven diseases, has announced the publication of new research identifying a novel, single-gene target for cellular rejuvenation.
OneChain Immunotherapeutics (OCI), a clinical-stage biotech company focused on the development of CAR-T therapies for the treatment of oncologic diseases, has announced the appointment of Barbara Krebs-Pohl as the new chair of the Board of Directors.
Mirai Bio (Mirai) has announced a strategic collaboration with Thermo Fisher Scientific to benefit the life sciences and genetic medicines marketplace.
NewBiologix has announced it has granted a non-exclusive technology license to ReciBioPharm to provide global biotech and pharma companies with access to NewBiologix’s Xcell-Eng-HEK293 cell lines.
Astraveus, the benchtop cell factory company, has announced that it has entered into a strategic partnership with The Netherlands Center for the Clinical Advancement of Stem Cell and Gene Therapies (NecstGen).
